DK3615034T3 - Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling - Google Patents

Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling Download PDF

Info

Publication number
DK3615034T3
DK3615034T3 DK18721722.9T DK18721722T DK3615034T3 DK 3615034 T3 DK3615034 T3 DK 3615034T3 DK 18721722 T DK18721722 T DK 18721722T DK 3615034 T3 DK3615034 T3 DK 3615034T3
Authority
DK
Denmark
Prior art keywords
talazoparib
rucaparib
veliparib
olaparib
azd
Prior art date
Application number
DK18721722.9T
Other languages
English (en)
Inventor
Barbara Wolff-Winiski
Anton STÜTZ
Petra Dörfler
Original Assignee
Akribes Biomedical Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akribes Biomedical Gmbh filed Critical Akribes Biomedical Gmbh
Application granted granted Critical
Publication of DK3615034T3 publication Critical patent/DK3615034T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18721722.9T 2017-04-28 2018-04-24 Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling DK3615034T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000743 2017-04-28
PCT/EP2018/060435 WO2018197463A1 (en) 2017-04-28 2018-04-24 Rucaparib, talazoparib, veliparib, olaparib and azd 2461 for treating impaired skin wound healing

Publications (1)

Publication Number Publication Date
DK3615034T3 true DK3615034T3 (da) 2021-08-23

Family

ID=58668702

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18721722.9T DK3615034T3 (da) 2017-04-28 2018-04-24 Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling

Country Status (6)

Country Link
US (1) US11638709B2 (da)
EP (1) EP3615034B1 (da)
AU (1) AU2018260096B2 (da)
CA (1) CA3096136A1 (da)
DK (1) DK3615034T3 (da)
WO (1) WO2018197463A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US20090263407A1 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing

Also Published As

Publication number Publication date
AU2018260096A1 (en) 2019-11-07
WO2018197463A1 (en) 2018-11-01
EP3615034B1 (en) 2021-06-02
CA3096136A1 (en) 2018-11-01
AU2018260096B2 (en) 2023-08-24
US11638709B2 (en) 2023-05-02
EP3615034A1 (en) 2020-03-04
US20200078369A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
DK3658539T3 (da) Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3600281T3 (da) Kombinationsbehandling til behandling eller forebyggelse af tumorer
IL269490B (en) Surface treatment methods and compositions therefor
IL262603B (en) Devices, systems and methods for treating medical devices having passageways with ozone gas
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
LT3658140T (lt) Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui
DK3640207T3 (da) Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf
DK3624796T3 (da) Pyrrolopyridin.anilinforbindelser til behandling af hudlidelse
EP3548003A4 (en) EXTRACELLULAR VESICLES AND THEIR METHODS AND USES
EP3758633A4 (en) IMPLANTS AND METHODS OF USE AND ASSEMBLY
EP3706068A4 (en) LAND USE DETERMINATION SYSTEM, LAND USE DETERMINATION METHOD AND PROGRAM
EP3547121A4 (en) COMBINATION DEVICE, METHOD AND PROGRAM
DK3532064T3 (da) Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
EP3582435A4 (en) BIOMETRIC SIGNATURE SYSTEM AND BIOMETRIC SIGNATURE PROCESS
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
DK3615034T3 (da) Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling
DK3529234T3 (da) Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
EP3728562A4 (en) HEART MICROTISSUE AND ASSOCIATED USES
DK3383871T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i behandling af cancer
EP3678672A4 (en) ALDOXORUBICIN-BASED METHODS AND POLYTHERAPIES